Explanation of Additional Errors in Report of Trial of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment

To the Editor On behalf of our coauthors, we write to report errors that occurred in the Original Investigation, “Evaluation of Low-Dose, Low-Frequency Oral Psoralen–UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial,”¹ that was published online March 20, 2019, and in the May print issue of JAMA Dermatology. This article reported the results of a trial in which 27 patients with mycosis fungoides (MF) were treated with oral 8-methoxypsoralen followed by UV-A exposure 2 times per week for 12 to 24 weeks until complete response (CR). Eleven patients with CR were randomly assigned to receive psoralen–UV-A (PUVA) photochemotherapy maintenance for 9 months and 8 patients with CR were randomly assigned to no maintenance.